A CYP3A4 interaction is any supplement or co-administered compound that meaningfully changes the activity of the CYP3A4 enzyme, the hepatic and intestinal protein that metabolizes a large share of prescription medications. When the enzyme is induced, paired drug levels can fall below their therapeutic range; when the enzyme is inhibited, levels can rise toward toxicity. Unfair flags this category at add-time because the same supplement can behave very differently depending on the prescription it sits next to.
Why this enzyme matters
CYP3A4 sits in the gut wall and the liver and processes roughly half of all metabolized prescription medications, including many statins, certain calcium-channel blockers, several immunosuppressants, common anticoagulants, and a broad set of psychiatric and oncology agents. Because the substrate list is wide, a single supplement change can shift the blood level of a drug the user already tolerated for years, which is why the interaction risk screen runs again every time a new prescription is logged.
Inducers and inhibitors most often seen in supplement stacks
Inducers speed up enzyme activity and can pull drug levels down. The most studied supplement-side inducer is St. John's Wort, which is documented to reduce exposure to several paired drugs by a clinically meaningful margin.
Inhibitors slow enzyme activity and can let drug levels climb. Examples that trigger review in the library include concentrated curcumin preparations with piperine, berberine, and grapefruit-derived furanocoumarins covered in the dedicated grapefruit entry.
The same compound can also act on transport proteins such as P-glycoprotein in parallel, which is why a CYP3A4 flag often travels with a transporter flag in the same metadata record.
Reading the pairing chart
The platform stores a per-compound inducer or inhibitor tag, the strength tier where data exists, and the prescription classes most often impacted. The chart is not a substitute for a pharmacist review; it is a starting point that tells the user when to ask a more specific question.
For users assembling a first roster, building your first supplement stack walks through how the prescription input field shapes which CYP3A4-active compounds are filtered out before the candidate list is shown.
What to do when a flag fires
When a flag fires, the app keeps the new supplement from activating until a prescriber or pharmacist has reviewed the pair against the specific medication on the chart. The prompt asks the user to record the exact product name so the pharmacist can read the active forms rather than the marketing name.
Limits of the screen
Published induction and inhibition data is denser for some prescription classes than others. The platform marks low-confidence pairs explicitly rather than presenting them as equivalent to well-studied pairs, and a missing flag does not prove the absence of an effect — it sometimes only reflects the absence of published data.
How this appears in Unfair
A CYP3A4 tag on a supplement intersects with the user's prescription profile at the add step. Matched pairs are held with a prescriber-question template pre-filled, and unmatched pairs are activated with a chart note so a later prescription change re-runs the screen.
Clinical safety note
CYP3A4 flags in the library are derived from public pharmacology references and are narrower than a prescriber's chart review. Any new prescription, change in prescription dose, or new symptom on a paired stack is a reason to involve a pharmacist or clinician before continuing.